Pasithea Therapeutics (Pasithea Therapeutics) Price-to-Tangible-Book : 0.56 (As of May. 11, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Price-to-Tangible-Book?

As of today (2024-05-11), Pasithea Therapeutics's share price is $7.6799. Pasithea Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $13.63. Hence, Pasithea Therapeutics's Price to Tangible Book Ratio of today is 0.56.

The historical rank and industry rank for Pasithea Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

KTTA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.51 Med: 0.54 Max: 0.79
Current: 0.56

During the past 4 years, Pasithea Therapeutics's highest Price to Tangible Book Ratio was 0.79. The lowest was 0.51. And the median was 0.54.

KTTA's Price-to-Tangible-Book is ranked better than
93.04% of 1221 companies
in the Biotechnology industry
Industry Median: 2.7 vs KTTA: 0.56

A closely related ratio is called PB Ratio. As of today, Pasithea Therapeutics's share price is $7.6799. Pasithea Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $22.46. Hence, Pasithea Therapeutics's P/B Ratio of today is 0.34.

Pasithea Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Pasithea Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics Price-to-Tangible-Book Chart

Pasithea Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

0.79

0.51

0.54

Pasithea Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial									0.51	0.33	0.49	0.53	0.54

Competitive Comparison of Pasithea Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Pasithea Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pasithea Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's Price-to-Tangible-Book falls into.

Pasithea Therapeutics Price-to-Tangible-Book Calculation

Pasithea Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	7.6799	/	13.627
	=	0.56

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Pasithea Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139

Website

https://www.pasithea.com

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.

Executives

Graeme Martin Currie	officer: Chief Development Officer	51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman	director	10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning	10 percent owner	200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc	10 percent owner	C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a	10 percent owner	C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd.	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney	other: Member of 10% owner group	C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian	other: Member of 10% owner group	350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak	director	325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc	other: Member of 10% owner group	350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp	other: Member of 10% owner group	CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc	other: Member of 10% owner group	1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977